Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

恩曲他滨 利比韦林 医学 替诺福韦-阿拉芬酰胺 杜鲁特格拉维尔 内科学 人口 耐受性 不利影响 人类免疫缺陷病毒(HIV) 病毒学 病毒载量 抗逆转录病毒疗法 环境卫生
作者
Moti N. Ramgopal,Antonella Castagna,Charles Cazanave,Vicens Díaz-Brito,Robin Henry Dretler,Shinichi Oka,Olayemi O. Osiyemi,Sharon Lynn Walmsley,James Sims,Giovanni Di Perri,Kenneth Sutton,Denise Sutherland‐Phillips,Alessandro Berni,Christine L Latham,Feifan Zhang,Ronald D. D'Amico,Miguel Pascual-Bernáldez,Rodica M Van Solingen-Ristea,Veerle Van Eygen,Parul Patel
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:10 (9): e566-e577 被引量:140
标识
DOI:10.1016/s2352-3018(23)00136-4
摘要

Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months. The SOLAR study aimed to compare long-acting cabotegravir plus rilpivirine every 2 months with continued once-daily bictegravir, emtricitabine, and tenofovir alafenamide for the maintenance of HIV-1 virological suppression in adults living with HIV.SOLAR is a randomised, open-label, multicentre, phase 3b, non-inferiority study. The study was done in 118 centres across 14 countries. Participants with HIV-1 RNA less than 50 copies per mL were randomly assigned (2:1), stratified by sex at birth and BMI, to either long-acting cabotegravir (600 mg) plus rilpivirine (900 mg) dosed intramuscularly every 2 months or to continue daily oral bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg). Participants randomly assigned to long-acting therapy had a choice to receive cabotegravir (30 mg) plus rilpivirine (25 mg) once daily as an optional oral lead-in for approximately 1 month. The primary efficacy endpoint was the proportion of participants with virological non-response (HIV-1 RNA ≥50 copies per mL; the US Food and Drug Administration snapshot algorithm, 4% non-inferiority margin; modified intention-to-treat exposed population) at month 11 (long-acting start with injections group) and month 12 (long-acting with oral lead-in group and bictegravir, emtricitabine, and tenofovir alafenamide group). The study is registered with ClinicalTrials.gov, NCT04542070, and is ongoing.837 participants were screened between Nov 9, 2020, and May 31, 2021, and 687 were randomly assigned to switch treatment or continue existing treatment. Of 670 participants (modified intention-to-treat exposed population), 447 (67%) switched to long-acting therapy (274 [61%] of 447 start with injections; 173 [39%] of 447 with oral lead-in) and 223 (33%) continued bictegravir, emtricitabine, and tenofovir alafenamide. Baseline characteristics were similar; median age was 37 years (range 18-74), 118 (18%) of 670 were female sex at birth, 207 (31%) of 670 were non-White, and median BMI was 25·9 kg/m2 (IQR 23·3-29·5). At month 11-12, long-acting cabotegravir plus rilpivirine showed non-inferior efficacy versus bictegravir, emtricitabine, and tenofovir alafenamide (HIV-1 RNA ≥50 copies per mL, five [1%] of 447 vs one [<1%] of 223), with an adjusted treatment difference of 0·7 (95% CI -0·7 to 2·0). Excluding injection site reactions, adverse events and serious adverse events were similar between groups. No treatment-related deaths occurred. More long-acting group participants had adverse events leading to withdrawal (25 [6%] of 454 vs two [1%] of 227). Injection site reactions were reported by 316 (70%) of 454 long-acting participants; most (98%) were grade 1 or 2.These data support the use of long-acting cabotegravir plus rilpivirine dosed every 2 months as a complete antiretroviral regimen that has similar efficacy to a commonly used integrase strand transfer inhibitor-based first-line regimen, while addressing unmet psychosocial issues associated with daily oral treatment.ViiV Healthcare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三的应助被19863737023采纳,获得10
刚刚
xiao端庄完成签到,获得积分10
刚刚
2秒前
2秒前
小张子完成签到,获得积分10
3秒前
1234完成签到,获得积分10
4秒前
4秒前
4秒前
Tong完成签到,获得积分10
5秒前
jiaminzhao完成签到,获得积分10
6秒前
思源的应助被大方的妙梦采纳,获得10
6秒前
6秒前
7秒前
8秒前
落叶发布了新的文献求助10
8秒前
YM发布了新的文献求助10
9秒前
mumu完成签到 ,获得积分10
9秒前
9秒前
Frank发布了新的文献求助10
10秒前
San发布了新的文献求助10
10秒前
英吉利25发布了新的文献求助10
12秒前
仁爱嫣完成签到,获得积分10
12秒前
嘞嘞累哦完成签到,获得积分10
13秒前
ding的应助被陈鸿超采纳,获得10
13秒前
ZRH发布了新的文献求助10
13秒前
jerry完成签到 ,获得积分10
14秒前
斤斤计较发布了新的文献求助10
15秒前
15秒前
15秒前
15秒前
Qingzhu完成签到,获得积分10
17秒前
何糖完成签到 ,获得积分10
17秒前
Maestro_S的应助被感动的樱桃采纳,获得10
17秒前
syvshc的应助被QINYUYU采纳,获得10
19秒前
FashionBoy的应助被likes采纳,获得10
19秒前
19秒前
研友_VZG7GZ的应助被yun采纳,获得30
20秒前
李小晴天完成签到,获得积分10
20秒前
20秒前
可爱玫瑰发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928